Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8790MR)

This product GTTS-WQ8790MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8790MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5276MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ11034MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ3938MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ340MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ13171MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ12132MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ10299MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ6009MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW